Multicenter randomized phase III study comparing docetaxel with carboplatin versus docetaxel single agent as second line treatment in patients with non-small cell lung cancer (NSCLC).
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2010
At a glance
- Drugs Docetaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jan 2009 Actual patient numbers (135) added as reported by ClinicalTrials.gov.
- 20 Jul 2008 Status changed recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2008 Actual end date is now 1 May 2008 as reported by ClinicalTrials.gov.